<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03513614</url>
  </required_header>
  <id_info>
    <org_study_id>2018-00838; ch20Weber2</org_study_id>
    <secondary_id>2018-000372-14</secondary_id>
    <nct_id>NCT03513614</nct_id>
  </id_info>
  <brief_title>Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS)</brief_title>
  <acronym>TAXIS</acronym>
  <official_title>Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS). A Multicenter Randomized Phase III Trial (OPBC-03/ SAKK 23/16 /IBCSG 57-18 / ABCSG-53 / GBG-101)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Austrian Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: The use of tailored axillary dissection as a tailored procedure will avoid&#xD;
      surgical overtreatment by selectively removing the lymph nodes that are affected by the&#xD;
      cancer, thereby sparing many women the unnecessary complications of a radical surgery,&#xD;
      providing a better quality of life while keeping the same efficacy.&#xD;
&#xD;
      PURPOSE: The phase III trial is evaluating the optimal treatment for breast cancer patients&#xD;
      in terms of surgery and radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The removal of all lymph nodes in the armpit through conventional axillary dissection has&#xD;
      been standard care for all patients with breast cancer for almost a century. In the nineties,&#xD;
      the sentinel lymph node procedure, which involves the selective removal of the first few&#xD;
      affected lymph nodes, was introduced in clinical practice. Today, conventional axillary&#xD;
      dissection is still performed on many women with breast cancer that has spread to the nodes.&#xD;
      It is the cause for relevant morbidity in the form of lymphedema, impairment of shoulder&#xD;
      mobility, sensation disorders and chronic pain in as much as one third of all women&#xD;
      undergoing the procedure.&#xD;
&#xD;
      The TAXIS trial will evaluate the optimal treatment for breast cancer patients in terms of&#xD;
      surgery and radiotherapy. In particular, it will investigate the value of tailored axillary&#xD;
      surgery (TAS), a new technique that aims at selectively removing the positive lymph nodes.&#xD;
      TAS combines the removal of palpably suspicious nodes with the sentinel procedure. TAS is a&#xD;
      promising procedure that may significantly decrease morbidity in breast cancer patients by&#xD;
      avoiding surgical overtreatment.&#xD;
&#xD;
      This trial has the potential to establish a new worldwide treatment standard with hopefully&#xD;
      less side effects and a better quality of life, while keeping the same efficacy as provided&#xD;
      by radical surgery.&#xD;
&#xD;
      The main objective of the trial is to show that TAS and axillary radiotherapy (RT) is&#xD;
      non-inferior to ALND in terms of disease-free survival of node positive breast cancer&#xD;
      patients at high risk of recurrence in the era of effective systemic therapy and extended&#xD;
      regional nodal irradiation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2018</start_date>
  <completion_date type="Anticipated">December 2034</completion_date>
  <primary_completion_date type="Anticipated">March 2034</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>at the occurrence of the event or latest 20 years after randomization of the last patient</time_frame>
    <description>The primary endpoint of this trial is DFS, defined as time from randomization until one of the following events, whichever comes first:&#xD;
Local recurrence, regional recurrence, distant recurrence&#xD;
Second breast cancer&#xD;
Death from any cause Patients not experiencing an event will be censored at the date of the last available assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>at the occurrence of the event or latest 20 years after randomization of the last patient</time_frame>
    <description>OS will be calculated from randomization until death from any cause. Patients not experiencing an event will be censored at the last date they were known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast cancer-specific survival (BCSS)</measure>
    <time_frame>at the occurrence of the event or latest 20 years after randomization of the last patient</time_frame>
    <description>BCSS will be calculated from randomization until death from breast cancer. Patients not experiencing an event will be censored at the last date they were known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to local recurrence (TTLR)</measure>
    <time_frame>at the occurrence of the event or latest 20 years after randomization of the last patient</time_frame>
    <description>TTLR will be calculated from randomization until local recurrence or death from breast cancer. Patients not experiencing an event or patients who died due to other reasons before experiencing an event will be censored at the date of the last available assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to distant recurrence (TTDR)</measure>
    <time_frame>at the occurrence of the event or latest 20 years after randomization of the last patient</time_frame>
    <description>TTDR will be calculated from randomization until distant recurrence or death from breast cancer. Patients not experiencing an event or patients who died due to other reasons before experiencing an event will be censored at the date of the last available assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician reported morbidity outcomes (Lymphedema)</measure>
    <time_frame>at baseline, at week 1 and 4 after surgery, before the beginning of radiotherapy. During follow-up: 9 and 12 months after randomization then every 6 months up to 3 years, then every year up to 20 years after randomization of the last patient.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician reported morbidity outcomes (Decreased range of shoulder motion)</measure>
    <time_frame>at baseline, at week 1 and 4 after surgery. During follow-up: 9 and 12 months after randomization then every 6 months up to 3 years, then every year up to 10 years after randomization of the last patient.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events according to NCI CTCAE v4.03</measure>
    <time_frame>from date of patient consent and up to 20 years after randomization of the last patient</time_frame>
    <description>Clipping-related AEs and specific AEs related to the surgical procedure and radiotherapy will be assessed according to NCI CTCAE v4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late radiotherapy-related adverse events</measure>
    <time_frame>from date of patient consent and up to 20 years after randomization of the last patient</time_frame>
    <description>Late adverse events related to the radiotherapy will be assessed according to the Late Effects in Normal Tissues-Subjective, Objective, Management and Analytic (LENT-SOMA) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical site infections (SSI)</measure>
    <time_frame>from date of patient consent and up to 20 years after randomization of the last patient</time_frame>
    <description>SSIs will be assessed according to the Centers for Disease Control and Prevention Surgical Site Infection Classification System.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Node-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ALND</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tailored axillary surgery followed by axillary lymph node dissection (ALND) and regional nodal irradiation excluding the dissected axilla.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No ALND</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tailored axillary surgery followed by regional nodal irradiation including the full axilla.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tailored axillary surgery - both Arms</intervention_name>
    <description>Axillary lymph node dissection - Arm A</description>
    <arm_group_label>ALND</arm_group_label>
    <arm_group_label>No ALND</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy - Arm A</intervention_name>
    <description>Regional nodal irradiation excluding the dissected axilla - Arm A</description>
    <arm_group_label>ALND</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy - Arm B</intervention_name>
    <description>Regional nodal irradiation including the full axilla - Arm B</description>
    <arm_group_label>No ALND</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria at pre-registration:&#xD;
&#xD;
          -  Written informed consent according to ICH/GCP regulations prior to any trial specific&#xD;
             procedures.&#xD;
&#xD;
          -  Breast cancer, node positive detected by palpation or imaging&#xD;
&#xD;
          -  Planned neoadjuvant treatment (e.g. chemotherapy or endocrine therapy) allowed&#xD;
&#xD;
          -  Female or male aged ≥ 18 years&#xD;
&#xD;
          -  Ability to complete the Quality of Life questionnaires&#xD;
&#xD;
        Inclusion criteria at registration:&#xD;
&#xD;
          -  Node-positive breast cancer (histologically or cytologically proven both in primary&#xD;
             tumor and in lymph node) AJCC/UICC [42] stage II-III (all molecular subtypes allowed):&#xD;
&#xD;
               -  Node-positivity detected by imaging (iN+) and confirmed by pathology without&#xD;
                  neoadjuvant treatment&#xD;
&#xD;
               -  Node-positivity detected by palpation (cN1-2) and confirmed by pathology without&#xD;
                  neoadjuvant treatment. Note: occult breast cancer is allowed, if biopsy-proven&#xD;
                  axillary lymphatic metastasis is present&#xD;
&#xD;
          -  Eligible for primary ALND or sentinel lymph node procedure with frozen section and&#xD;
             either:&#xD;
&#xD;
               -  Newly diagnosed&#xD;
&#xD;
               -  Isolated in-breast recurrence or second ipsilateral breast cancer (at least 5&#xD;
                  years disease free and no prior axillary surgery or loco regional RT)&#xD;
&#xD;
          -  Baseline Quality of Life questionnaire has been completed&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Adequate condition for general anesthesia and breast cancer surgery&#xD;
&#xD;
          -  Women with child-bearing potential are using effective contraception, are not pregnant&#xD;
             or lactating and agree not to become pregnant during trial treatment and thereafter&#xD;
             during the time recommended by the guidelines for adjuvant systemic therapies. A&#xD;
             negative pregnancy test before inclusion into the trial is required for all women with&#xD;
             child-bearing potential.&#xD;
&#xD;
          -  Men agree not to father a child during trial treatment and thereafter during 6 months.&#xD;
&#xD;
        Inclusion criteria at randomization (intraoperatively)&#xD;
&#xD;
          -  Node-positive breast cancer (histologically or cytologically proven both in primary&#xD;
             tumor and in lymph node) AJCC/UICC [42] stage II-III (all molecular subtypes allowed):&#xD;
&#xD;
               -  Node-positivity initially detected by imaging (negative on palpation) and&#xD;
                  reconfirmed by pathology (residual disease) (in SLN or non SLN during surgery)&#xD;
                  after neoadjuvant treatment&#xD;
&#xD;
               -  Node-positivity initially detected by palpation and reconfirmed by pathology&#xD;
                  (residual disease) after neoadjuvant treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion criteria at pre-registration:&#xD;
&#xD;
        Any potential patient who meets any of the following criteria has to be excluded from&#xD;
        entering the trial.&#xD;
&#xD;
          -  Clinical N3 breast cancer&#xD;
&#xD;
          -  Clinical N2 breast cancer, if limited to the internal mammary nodes only&#xD;
&#xD;
          -  Contralateral breast cancer&#xD;
&#xD;
          -  Prior axillary surgery (except prior sentinel node procedure in breast recurrence)&#xD;
&#xD;
          -  Prior regional radiotherapy&#xD;
&#xD;
          -  History of hematologic or primary solid tumor malignancy, unless in remission for at&#xD;
             least 5 years from pre-registration with the exception of adequately treated cervical&#xD;
             carcinoma in situ or localized non-melanoma skin cancer.&#xD;
&#xD;
          -  Concurrent treatment with any other experimental drug within 30 days of&#xD;
             pre-registration&#xD;
&#xD;
          -  Concomitant use of other anti-cancer drugs or radiotherapy&#xD;
&#xD;
          -  Any other serious underlying medical, psychiatric, psychological, familial or&#xD;
             geographical condition, which in the judgment of the investigator may interfere with&#xD;
             the planned staging, treatment and follow-up, affect patient compliance or place the&#xD;
             patient at high risk from treatment-related complications.&#xD;
&#xD;
        Exclusion criteria at randomization (intraoperatively):&#xD;
&#xD;
        Any potential patient who meets any of the following criteria has to be excluded from the&#xD;
        trial.&#xD;
&#xD;
          -  Absence of clip in the specimen radiography&#xD;
&#xD;
          -  No palpable disease left behind in the axilla during Tailored Axillary Surgery&#xD;
&#xD;
          -  Sentinel lymph node outside the axilla&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter P. Weber, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Walter P. Weber, Prof.</last_name>
    <phone>+41 61 328 61 49</phone>
    <email>walter.weber@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra Schulz</last_name>
    <phone>+41 61 328 5401</phone>
    <email>alexandra.schulz@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Krankenhaus Dornbirn</name>
      <address>
        <city>Dornbirn</city>
        <zip>6850</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Hager, MD</last_name>
      <phone>+43 5572 303 2490</phone>
      <email>christopher.hager@dornbirn.at</email>
    </contact>
    <investigator>
      <last_name>Christopher Hager, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <zip>6800</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Burghard Abendstein, MD</last_name>
      <phone>+43 5522 303 2200</phone>
      <email>Burghard.Abendstein@vlkh.net</email>
    </contact>
    <investigator>
      <last_name>Burghard Abendstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tirol Kliniken - Landeskrankenhaus Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Egle, MD</last_name>
      <phone>+43 5050 423 073</phone>
      <email>daniel.egle@tirol-kliniken.at</email>
    </contact>
    <investigator>
      <last_name>Daniel Egle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ordens Kinikum Linz, Barmherzige Schwestern</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dietmar Heck, MD</last_name>
      <phone>+43 7327 677 7300</phone>
      <email>dietmar.heck@ordensklinikum.at</email>
    </contact>
    <investigator>
      <last_name>Dietmar Heck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskrichen GmbH</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Reisenberger, MD</last_name>
      <phone>+43 7242 415 3452</phone>
      <email>klaus.reisenberger@klinikum-wegr.at</email>
    </contact>
    <investigator>
      <last_name>Klaus Reisenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien - Klinik für Chirurgie</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Exner, MD</last_name>
      <phone>+43 676 92 32 885</phone>
      <email>ruth.exner@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Ruth Exner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien - Universitätsklinik für Frauenheilkunde</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Singer, Prof</last_name>
      <phone>+43 140 400 280 10</phone>
      <email>christian.singer@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Christian Singer, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ev. Waldkrankenhaus Spandau</name>
      <address>
        <city>Berlin</city>
        <zip>13589</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>KEM | Evang. Kliniken Essen-Mitte gGmbH</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mattea Reinisch, MD</last_name>
      <phone>+49 201 174 33005</phone>
      <email>m.reinisch@kem-med.com</email>
    </contact>
    <investigator>
      <last_name>Mattea Reinisch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niels-Stensen-Kliniken Franziskus-Hospital Harderberg</name>
      <address>
        <city>Georgsmarienhütte</city>
        <zip>49124</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Beckmann, MD</last_name>
      <phone>+49 541 5022254</phone>
      <email>ulrike.beckmann@niels-stensen-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Ulrike Beckmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Heil, Prof</last_name>
      <phone>+49 6221 56 7883</phone>
      <email>joerg.heil@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Jörg Heil, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ViDia Christliche Kliniken Karlsruhe, Diakonissenkrankenhaus</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sibylle Perez, MD</last_name>
      <phone>+49 721 8898314</phone>
      <email>s.perez@diak-ka.de</email>
    </contact>
    <investigator>
      <last_name>Sibylle Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologie Rheinsieg</name>
      <address>
        <city>Troisdorf</city>
        <zip>53840</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Helios University Hospital Wuppertal</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vesna Bjelic-Radisic, Prof</last_name>
      <phone>+49 202 896 1411</phone>
      <email>vesna.bjelic-radisic@helios-gesundheit.de</email>
    </contact>
    <investigator>
      <last_name>Vesna Bjelic-Radisic, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoltán Mátrai, PhD, MD</last_name>
      <phone>+36 1 224 8600 3302</phone>
      <email>matraidok@oncol.hu</email>
    </contact>
    <investigator>
      <last_name>Zoltán Mátrai, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Country Hospital</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Maráz, MD</last_name>
      <phone>+36 76 516 700</phone>
      <email>marazr@kmk.hu</email>
    </contact>
    <investigator>
      <last_name>Robert Maráz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Szeged</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ospedale MultiMedica Castellanza</name>
      <address>
        <city>Castellanza</city>
        <zip>21053</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Institut</name>
      <address>
        <city>Vilnius</city>
        <zip>08660</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerijus Ostapenko, Prof</last_name>
      <phone>+370 5 278 68 14</phone>
      <email>valerijus.ostapenko@nvi.lt</email>
    </contact>
    <investigator>
      <last_name>Valerijus Ostapenko, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitri Sarlos, MD</last_name>
      <phone>+41 62 838 50 65</phone>
      <email>Dimitri.Sarlos@ksa.ch</email>
    </contact>
    <investigator>
      <last_name>Dimitri Sarlos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Basel und Netzwerk</name>
      <address>
        <city>Allschwil</city>
        <zip>4123</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jelena Winkler, MD</last_name>
      <phone>+41 61 485 94 00</phone>
      <email>jelena.winkler@aerztehaus-allschwil.ch</email>
    </contact>
    <investigator>
      <last_name>Jelena Winkler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelia Leo, MD</last_name>
      <phone>+41 56 486 36 36</phone>
      <email>cornelia.leo@ksb.ch</email>
    </contact>
    <investigator>
      <last_name>Cornelia Leo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4051</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Weber, Prof</last_name>
      <phone>+41 61 328 61 49</phone>
      <email>walter.weber@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Walter Weber, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Claraspital AG</name>
      <address>
        <city>Basel</city>
        <zip>CH-4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Brustzentrum, Klinik Engeried</name>
      <address>
        <city>Bern</city>
        <zip>3012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Berclaz, MD</last_name>
      <phone>+41 31 309 95 30</phone>
      <email>gilles.berclaz@lindenhofgruppe.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique de Grangettes</name>
      <address>
        <city>Chêne-Bougeries</city>
        <zip>1224</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Conny Vrieling, MD</last_name>
      <phone>+41 22 545 80 80</phone>
      <email>conny.vrieling@grangettes.ch</email>
    </contact>
    <investigator>
      <last_name>Conny Vrieling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Thurgau</name>
      <address>
        <city>Frauenfeld</city>
        <zip>8501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Fehr, Prof</last_name>
      <phone>+41 52 723 72 56</phone>
      <email>mathias.fehr@stgag.ch</email>
    </contact>
    <investigator>
      <last_name>Mathias Fehr, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cantonal Fribourgeois</name>
      <address>
        <city>Fribourg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karine Clerc, MD</last_name>
      <phone>+41 26 919 64 64</phone>
      <email>dr.karine.clerc@websud.ch</email>
    </contact>
    <investigator>
      <last_name>Karine Clerc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de Genolier</name>
      <address>
        <city>Genolier</city>
        <zip>1272</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Kohlik, MD</last_name>
      <phone>+41 22 362 60 00</phone>
      <email>mkohlik@genolier.net</email>
    </contact>
    <investigator>
      <last_name>Magdalena Kohlik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HUG - Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Genève</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giang Thanh Lam, MD</last_name>
      <phone>+41 22 372 40 14</phone>
      <email>giang.t.lam@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Giang Thanh Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital neuchâtelois</name>
      <address>
        <city>La Chaux-de-Fonds</city>
        <zip>2300</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Becciolini, MD</last_name>
      <phone>+41 32 967 25 31</phone>
      <email>charles.becciolini@ne.ch</email>
    </contact>
    <investigator>
      <last_name>Charles Becciolini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois CHUV</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc Lelièvre, MD</last_name>
      <phone>+41 21 314 32 69</phone>
      <email>loic.lelievre@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Loïc Lelièvre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hirslanden Klinik St. Anna</name>
      <address>
        <city>Lucerne</city>
        <zip>6006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Dubsky, Prof</last_name>
      <phone>+41 41 208 37 54</phone>
      <email>peter.dubsky@hirslanden.ch</email>
    </contact>
    <investigator>
      <last_name>Peter Dubsky, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital - Brustzentrum</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Bucher, MD</last_name>
      <phone>+41 41 205 28 00</phone>
      <email>susanne.bucher@luks.ch</email>
    </contact>
    <investigator>
      <last_name>Susanne Bucher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bethesda Spital Basel, Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Pratteln</city>
        <zip>4133</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dieter Johann Mueller, Dr. med.</last_name>
      <phone>+41 61 823 77 00</phone>
      <email>Dieter.mueller@hin.ch</email>
    </contact>
    <investigator>
      <last_name>Dieter Johann Mueller, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spital Limmattal</name>
      <address>
        <city>Schlieren</city>
        <zip>8952</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Naydina Ragaz, MD</last_name>
      <phone>+41 44 736 82 32</phone>
      <email>Tatiana.Naydina@spital-limmattal.ch</email>
    </contact>
    <investigator>
      <last_name>Tatiana Naydina Ragaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital du Valais / Hôpital de Sion</name>
      <address>
        <city>Sion</city>
        <zip>1951</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colin Simonson, MD</last_name>
      <phone>+41 27 603 45 01</phone>
      <email>colin.simonson@hopitalvs.ch</email>
    </contact>
    <investigator>
      <last_name>Colin Simonson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pagona Markellou, MD</last_name>
      <phone>+41 71 494 20 26</phone>
      <email>Pagona.Markellou@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Pagona Markellou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Ostschweiz</name>
      <address>
        <city>St. Gallen</city>
        <zip>9016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Knauer, MD</last_name>
      <phone>+41 71 552 33 33</phone>
      <email>michael.knauer@bz-ost.ch</email>
    </contact>
    <investigator>
      <last_name>Michael Knauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur, Brustzentrum</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rok Satler, MD</last_name>
      <phone>+41 52 266 48 91</phone>
      <email>rok.satler@ksw.ch</email>
    </contact>
    <investigator>
      <last_name>Rok Satler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spital Zollikerberg</name>
      <address>
        <city>Zollikerberg</city>
        <zip>8125</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hisham Fansa, Prof</last_name>
      <phone>+41 44 397 38 61</phone>
      <email>hisham.fansa@spitalzollikerberg.ch</email>
    </contact>
    <investigator>
      <last_name>Hisham Fansa, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brust-Zentrum Seefeld</name>
      <address>
        <city>Zürich</city>
        <zip>8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Tausch, MD</last_name>
      <phone>+41 44 380 76 60</phone>
      <email>c.tausch@brust-zentrum.ch</email>
    </contact>
    <investigator>
      <last_name>Christoph Tausch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zürich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Gabriel, MD</last_name>
      <phone>+41 44 416 20 04</phone>
      <email>Natalie.Gabriel@triemli.zuerich.ch</email>
    </contact>
    <investigator>
      <last_name>Natalie Gabriel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts Spital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantin Dedes, MD</last_name>
      <phone>+41 44 255 11 11</phone>
      <email>konstantin.dedes@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Konstantin Dedes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Weber WP, Matrai Z, Hayoz S, Tausch C, Henke G, Zwahlen DR, Gruber G, Zimmermann F, Seiler S, Maddox C, Ruhstaller T, Muenst S, Ackerknecht M, Kuemmel S, Bjelic-Radisic V, Kurzeder C, Újhelyi M, Vrieling C, Satler R, Meyer I, Becciolini C, Bucher S, Simonson C, Fehr PM, Gabriel N, Maráz R, Sarlos D, Dedes KJ, Leo C, Berclaz G, Dubsky P, Exner R, Fansa H, Hager C, Reisenberger K, Singer CF, Reitsamer R, Reinisch M, Winkler J, Lam GT, Fehr MK, Naydina T, Kohlik M, Clerc K, Ostapenko V, Fitzal F, Nussbaumer R, Maggi N, Schulz A, Markellou P, Lelièvre L, Egle D, Heil J, Knauer M. Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). Breast. 2021 Sep 8;60:98-110. doi: 10.1016/j.breast.2021.09.004. [Epub ahead of print]</citation>
    <PMID>34555676</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 19, 2018</study_first_submitted>
  <study_first_submitted_qc>April 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2018</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tailored Axillary Surgery</keyword>
  <keyword>TAXIS</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>node-positive breast cancer</keyword>
  <keyword>phase III trial</keyword>
  <keyword>IBCSG 57-18</keyword>
  <keyword>ABCSG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

